Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 763 entries
Sorted by: Best Match Show Resources per page
Differences in BCG vaccination and tuberculin skin-test positivity.

The Lancet. Infectious diseases

Sidibe A, Matteelli A, Menzies R, Getahun H.
PMID: 26333326
Lancet Infect Dis. 2015 Sep;15(9):1003. doi: 10.1016/S1473-3099(15)00233-9.

No abstract available.

Cite
Sidibe A, Matteelli A, Menzies R, et al. Differences in BCG vaccination and tuberculin skin-test positivity. Lancet Infect Dis. 2015;15(9):1003doi: 10.1016/S1473-3099(15)00233-9.
Sidibe, A., Matteelli, A., Menzies, R., & Getahun, H. (2015). Differences in BCG vaccination and tuberculin skin-test positivity. The Lancet. Infectious diseases, 15(9), 1003. https://doi.org/10.1016/S1473-3099(15)00233-9
Sidibe, Anissa, et al. "Differences in BCG vaccination and tuberculin skin-test positivity." The Lancet. Infectious diseases vol. 15,9 (2015): 1003. doi: https://doi.org/10.1016/S1473-3099(15)00233-9
Sidibe A, Matteelli A, Menzies R, Getahun H. Differences in BCG vaccination and tuberculin skin-test positivity. Lancet Infect Dis. 2015 Sep;15(9):1003. doi: 10.1016/S1473-3099(15)00233-9. PMID: 26333326; PMCID: PMC5642862.
Copy Download .nbib Format: NLM
FDA approves broad hepatitis C treatment.

The Lancet. Infectious diseases

Mushtaq A.
PMID: 27676353
Lancet Infect Dis. 2016 Oct;16(10):1118-1119. doi: 10.1016/S1473-3099(16)30344-9. Epub 2016 Sep 19.

No abstract available.

Cite
Mushtaq A. FDA approves broad hepatitis C treatment. Lancet Infect Dis. 2016;16(10):1118-1119doi: 10.1016/S1473-3099(16)30344-9.
Mushtaq, A. (2016). FDA approves broad hepatitis C treatment. The Lancet. Infectious diseases, 16(10), 1118-1119. https://doi.org/10.1016/S1473-3099(16)30344-9
Mushtaq, Ammara. "FDA approves broad hepatitis C treatment." The Lancet. Infectious diseases vol. 16,10 (2016): 1118-1119. doi: https://doi.org/10.1016/S1473-3099(16)30344-9
Mushtaq A. FDA approves broad hepatitis C treatment. Lancet Infect Dis. 2016 Oct;16(10):1118-1119. doi: 10.1016/S1473-3099(16)30344-9. Epub 2016 Sep 19. PMID: 27676353.
Copy Download .nbib Format: NLM
Correction.

The Lancet. Infectious diseases

[No authors listed]
PMID: 26122437
Lancet Infect Dis. 2015 Jul;15(7):761. doi: 10.1016/S1473-3099(15)00090-0. Epub 2015 Jun 03.

ENCORE1 Study Group. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis 2015; published online April 13. http://dx.doi.org/10.1016/S1473- 3099(15)70060-5—In this Article, the numbers...

Cite
Correction. Lancet Infect Dis. 2015;15(7):761doi: 10.1016/S1473-3099(15)00090-0.
(2015). Correction. The Lancet. Infectious diseases, 15(7), 761. https://doi.org/10.1016/S1473-3099(15)00090-0
"Correction." The Lancet. Infectious diseases vol. 15,7 (2015): 761. doi: https://doi.org/10.1016/S1473-3099(15)00090-0
Correction. Lancet Infect Dis. 2015 Jul;15(7):761. doi: 10.1016/S1473-3099(15)00090-0. Epub 2015 Jun 03. PMID: 26122437.
Copy Download .nbib Format: NLM
Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.

The Lancet. Infectious diseases

Waight PA, Andrews NJ, Ladhani NJ, Sheppard CL, Slack MP, Miller E.
PMID: 26008826
Lancet Infect Dis. 2015 Jun;15(6):629. doi: 10.1016/S1473-3099(15)00028-6. Epub 2015 May 17.

No abstract available.

Cite
Waight PA, Andrews NJ, Ladhani NJ, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(6):629doi: 10.1016/S1473-3099(15)00028-6.
Waight, P. A., Andrews, N. J., Ladhani, N. J., Sheppard, C. L., Slack, M. P., & Miller, E. (2015). Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. The Lancet. Infectious diseases, 15(6), 629. https://doi.org/10.1016/S1473-3099(15)00028-6
Waight, Pauline A, et al. "Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study." The Lancet. Infectious diseases vol. 15,6 (2015): 629. doi: https://doi.org/10.1016/S1473-3099(15)00028-6
Waight PA, Andrews NJ, Ladhani NJ, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015 Jun;15(6):629. doi: 10.1016/S1473-3099(15)00028-6. Epub 2015 May 17. PMID: 26008826; PMCID: PMC7130081.
Copy Download .nbib Format: NLM
Ebola: the real lessons from HIV scale-up.

The Lancet. Infectious diseases

Althaus CL.
PMID: 26008829
Lancet Infect Dis. 2015 Jun;15(6):629. doi: 10.1016/S1473-3099(15)70033-2. Epub 2015 Apr 24.

No abstract available.

Cite
Althaus CL. Ebola: the real lessons from HIV scale-up. Lancet Infect Dis. 2015;15(6):629doi: 10.1016/S1473-3099(15)70033-2.
Althaus, C. L. (2015). Ebola: the real lessons from HIV scale-up. The Lancet. Infectious diseases, 15(6), 629. https://doi.org/10.1016/S1473-3099(15)70033-2
Althaus, Christian L. "Ebola: the real lessons from HIV scale-up." The Lancet. Infectious diseases vol. 15,6 (2015): 629. doi: https://doi.org/10.1016/S1473-3099(15)70033-2
Althaus CL. Ebola: the real lessons from HIV scale-up. Lancet Infect Dis. 2015 Jun;15(6):629. doi: 10.1016/S1473-3099(15)70033-2. Epub 2015 Apr 24. PMID: 26008829.
Copy Download .nbib Format: NLM
Corrections. The expanding role of co-trimoxazole in developing countries.

The Lancet. Infectious diseases

Church JA, Fitzgerald F, Walker AS, Gibb DM.
PMID: 25749219
Lancet Infect Dis. 2015 Mar;15(3):263. doi: 10.1016/S1473-3099(14)71012-6. Epub 2015 Jan 22.

No abstract available.

Cite
Church JA, Fitzgerald F, Walker AS, et al. Corrections. The expanding role of co-trimoxazole in developing countries. Lancet Infect Dis. 2015;15(3):263doi: 10.1016/S1473-3099(14)71012-6.
Church, J. A., Fitzgerald, F., Walker, A. S., & Gibb, D. M. (2015). Corrections. The expanding role of co-trimoxazole in developing countries. The Lancet. Infectious diseases, 15(3), 263. https://doi.org/10.1016/S1473-3099(14)71012-6
Church, J A, et al. "Corrections. The expanding role of co-trimoxazole in developing countries." The Lancet. Infectious diseases vol. 15,3 (2015): 263. doi: https://doi.org/10.1016/S1473-3099(14)71012-6
Church JA, Fitzgerald F, Walker AS, Gibb DM. Corrections. The expanding role of co-trimoxazole in developing countries. Lancet Infect Dis. 2015 Mar;15(3):263. doi: 10.1016/S1473-3099(14)71012-6. Epub 2015 Jan 22. PMID: 25749219.
Copy Download .nbib Format: NLM
Corrections. Hospital organisation, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus.

The Lancet. Infectious diseases

Zingg W, Holmes A, Dettenkofer M.
PMID: 25749221
Lancet Infect Dis. 2015 Mar;15(3):263. doi: 10.1016/S1473-3099(15)70069-1.

No abstract available.

Cite
Zingg W, Holmes A, Dettenkofer M. Corrections. Hospital organisation, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus. Lancet Infect Dis. 2015;15(3):263doi: 10.1016/S1473-3099(15)70069-1.
Zingg, W., Holmes, A., & Dettenkofer, M. (2015). Corrections. Hospital organisation, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus. The Lancet. Infectious diseases, 15(3), 263. https://doi.org/10.1016/S1473-3099(15)70069-1
Zingg, W, et al. "Corrections. Hospital organisation, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus." The Lancet. Infectious diseases vol. 15,3 (2015): 263. doi: https://doi.org/10.1016/S1473-3099(15)70069-1
Zingg W, Holmes A, Dettenkofer M. Corrections. Hospital organisation, management, and structure for prevention of health-care-associated infection: a systematic review and expert consensus. Lancet Infect Dis. 2015 Mar;15(3):263. doi: 10.1016/S1473-3099(15)70069-1. PMID: 25749221.
Copy Download .nbib Format: NLM
Corrections.

The Lancet. Infectious diseases

[No authors listed]
PMID: 29050857
Lancet Infect Dis. 2017 Dec;17(12):1232. doi: 10.1016/S1473-3099(17)30596-0. Epub 2017 Oct 16.

No abstract available.

Cite
Corrections. Lancet Infect Dis. 2017;17(12):1232doi: 10.1016/S1473-3099(17)30596-0.
(2017). Corrections. The Lancet. Infectious diseases, 17(12), 1232. https://doi.org/10.1016/S1473-3099(17)30596-0
"Corrections." The Lancet. Infectious diseases vol. 17,12 (2017): 1232. doi: https://doi.org/10.1016/S1473-3099(17)30596-0
Corrections. Lancet Infect Dis. 2017 Dec;17(12):1232. doi: 10.1016/S1473-3099(17)30596-0. Epub 2017 Oct 16. PMID: 29050857.
Copy Download .nbib Format: NLM
Corrections.

The Lancet. Infectious diseases

[No authors listed]
PMID: 28653628
Lancet Infect Dis. 2017 Jul;17(7):689. doi: 10.1016/S1473-3099(17)30346-8. Epub 2017 Jun 21.

No abstract available.

Cite
Corrections. Lancet Infect Dis. 2017;17(7):689doi: 10.1016/S1473-3099(17)30346-8.
(2017). Corrections. The Lancet. Infectious diseases, 17(7), 689. https://doi.org/10.1016/S1473-3099(17)30346-8
"Corrections." The Lancet. Infectious diseases vol. 17,7 (2017): 689. doi: https://doi.org/10.1016/S1473-3099(17)30346-8
Corrections. Lancet Infect Dis. 2017 Jul;17(7):689. doi: 10.1016/S1473-3099(17)30346-8. Epub 2017 Jun 21. PMID: 28653628; PMCID: PMC8445356.
Copy Download .nbib Format: NLM
Corrections.

The Lancet. Infectious diseases

[No authors listed]
PMID: 28462810
Lancet Infect Dis. 2017 Jun;17(6):576. doi: 10.1016/S1473-3099(17)30239-6. Epub 2017 Apr 24.

No abstract available.

Cite
Corrections. Lancet Infect Dis. 2017;17(6):576doi: 10.1016/S1473-3099(17)30239-6.
(2017). Corrections. The Lancet. Infectious diseases, 17(6), 576. https://doi.org/10.1016/S1473-3099(17)30239-6
"Corrections." The Lancet. Infectious diseases vol. 17,6 (2017): 576. doi: https://doi.org/10.1016/S1473-3099(17)30239-6
Corrections. Lancet Infect Dis. 2017 Jun;17(6):576. doi: 10.1016/S1473-3099(17)30239-6. Epub 2017 Apr 24. PMID: 28462810.
Copy Download .nbib Format: NLM
Corrections.

The Lancet. Infectious diseases

[No authors listed]
PMID: 28624263
Lancet Infect Dis. 2017 Sep;17(9):897. doi: 10.1016/S1473-3099(17)30391-2. Epub 2017 Jun 15.

No abstract available.

Cite
Corrections. Lancet Infect Dis. 2017;17(9):897doi: 10.1016/S1473-3099(17)30391-2.
(2017). Corrections. The Lancet. Infectious diseases, 17(9), 897. https://doi.org/10.1016/S1473-3099(17)30391-2
"Corrections." The Lancet. Infectious diseases vol. 17,9 (2017): 897. doi: https://doi.org/10.1016/S1473-3099(17)30391-2
Corrections. Lancet Infect Dis. 2017 Sep;17(9):897. doi: 10.1016/S1473-3099(17)30391-2. Epub 2017 Jun 15. PMID: 28624263; PMCID: PMC6880283.
Copy Download .nbib Format: NLM
Looking back at yellow fever in Angola.

The Lancet. Infectious diseases

Bagcchi S.
PMID: 28244394
Lancet Infect Dis. 2017 Mar;17(3):269-270. doi: 10.1016/S1473-3099(17)30064-6. Epub 2017 Feb 23.

No abstract available.

Cite
Bagcchi S. Looking back at yellow fever in Angola. Lancet Infect Dis. 2017;17(3):269-270doi: 10.1016/S1473-3099(17)30064-6.
Bagcchi, S. (2017). Looking back at yellow fever in Angola. The Lancet. Infectious diseases, 17(3), 269-270. https://doi.org/10.1016/S1473-3099(17)30064-6
Bagcchi, Sanjeet. "Looking back at yellow fever in Angola." The Lancet. Infectious diseases vol. 17,3 (2017): 269-270. doi: https://doi.org/10.1016/S1473-3099(17)30064-6
Bagcchi S. Looking back at yellow fever in Angola. Lancet Infect Dis. 2017 Mar;17(3):269-270. doi: 10.1016/S1473-3099(17)30064-6. Epub 2017 Feb 23. PMID: 28244394.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 763 entries